smoking cessation

Varenicline dihydrochloride is a Selective α4β2 nicotinic acetylcholine receptor partial agonist.

Lazabemide (Ro 19-6327) is a selective and reversible monoamine oxidase B (MAO-B) inhibitor with IC50 values of 0.03 μM for MAO-B and >100 μM for MAO-A.

Lazabemide hydrochloride (N-(2-Aminoethyl)-5-chlor-2-pyridincarbox) is a reversible and selective mao-b inhibitor(Ki:7.9nM).

Varenicline Tartrate (CP 526555-18) is a benzazepine derivative that functions as an ALPHA4/BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.

3-Phenylthiophene (Compound 25) is a CYP2A6 inhibitor with a Ki of 3.3 μM. It exhibits Ki values of 9.7, 14, 112, and 107 μM for CYP2E1, CYP2B6, CYP2C9, and CYP2C19, respectively, and shows no significant inhibition of CYP3A4 and CYP2D6. 3-Phenylthiophene is applicable for smoking cessation research.

Lobelin sulphate is an alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has a variety of therapeutic uses including in insomnia, and smoking cessation, peripheral vascular disorders, respiratory disor

Varenicline Hydrochloride (CP 526555) is an orally active partial agonist of the α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is recognized as the principal mediator of nicotine dependence, and its pharmacological effect is critical in modulating addictive behaviors associated with nicotine exposure. Varenicline Hydrochloride (CP 526555) blocks the direct agonist effects of nicotine on nicotinic acetylcholine receptors while simultaneously stimulating these receptors in a more moderate and controlled manner, making it a widely used research compound in smoking cessation.

Lobeline, (+)- is an alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, a

Nicotine is a naturally produced alkaloid in the nightshade family of plants (most predominantly in tobacco and Duboisia hopwoodii) and is widely used recreationally as a stimulant and anxiolytic. As a pharmaceutical drug, it is used for smoking cessation to relieve withdrawal symptoms. Nicotine acts as a receptor agonist at most nicotinic acetylcholine receptors (nAChRs), except at two nicotinic receptor subunits (nAChRα9 and nAChRα10) where it acts as a receptor antagonist.

Nortriptyline is an antidepressant compound that enhances corticosteroid sensitivity of blood T-cells in patients with chronic obstructive pulmonary disease (COPD) and may be used for smoking cessation.

α-Conotoxin TxID is a potent antagonist of the α3β4 nicotinic acetylcholine receptor (nAChR) with an inhibitory half-maximal inhibitory concentration (IC50) of 12.5 nM. Its inhibitory activity is weaker against the closely related α6/α3β4 nAChR, with an IC50 of 94 nM. This compound holds potential for the development of novel smoking cessation drugs [1].

Desoxypeganine (Deoxypeganine) is an inhibitor of cholinesterase. It acting preferentially on butyrylcholinesterase, and as a selective inhibitor of monoamine oxidase A but not monoamine oxidase B.Desoxypeganine is being developed for its potential utility in the pharmacological treatment of alcohol abuse to reduce craving and depression in alcohol abusers, and might also be useful as a smoking cessation aid.

Varenicline-D4 hydrochloride is a deuterium-labeled form of Varenicline (dihydrochloride). Varenicline hydrochloride (T23502) acts as a partial agonist for the α4β2 nicotinic acetylcholine receptor (α4β2nAChR), with an EC50 of 2.3 μM. It serves as a full agonist for α3β4nAChR and α7nAChR, with EC50 values of 55 μM and 18 μM, respectively. As a nicotine ligand based on a cytosine structure, Varenicline dihydrochloride is utilized in smoking cessation research.

Varenicline-D4 is a deuterium-labeled form of Varenicline. Varenicline (T4246L) (CP 526555) acts as a partial agonist of the α4β2 nAChR nicotinic acetylcholine receptor, with an EC50 of 2.3 μM. It is a full agonist for the α3β4 nAChR and α7 nAChR acetylcholine receptors, with EC50 values of 55 μM and 18 μM, respectively. As a nicotine ligand based on the cytisine structure, Varenicline (T4246L) shows potential for use in smoking cessation research.